Medication reconciliation is essential to preventing medication errors and helping patients adhere to their treatment. It brings together all the key players involved in the patient’s health care treatment to optimize patient safety and strengthen coordinated care. With Synapse Platform, HCPs can rely on a robust, but also intuitive medication reconciliation technology to prevent medication errors and improve patient safety.
A digital solution that meets the needs of hospital pharmacists
Synapse Platform’s medication reconciliation solution is continuously improving based on user feedback and supports you at every key stage of the process.
- Without Synapse Platform
- With Synapse Platform
Without Synapse Platform
An unoptimized process
Without Synapse Platform, the medication reconciliation process is mainly done manually which can lead to data discrepancies and human errors. Hence, this manual process is time-consuming for hospital pharmacists, and the communication between HCPs is not facilitated, which can harm patient safety.
Our partnership with AP-HP (Paris Public Hospitals) and Sorbonne Université
Thierry Le MarecHospital Pharmacist, AP-HP Sorbonne Université
« Synapse Medicine has a dynamic, and reliable team with whom we have been able to develop a digital, user-oriented medication reconciliation tool.
When doing medication reconciliation, the whole process of entering and interpreting the patient’s treatments often takes a long time. This is usually done on paper or in Excel spreadsheets, which can lead to errors. Our partnership with Synapse Medicine has allowed us to change the way we think about medication reconciliation: it is reassuring, it makes routine clinical pharmacy activities much easier and faster. »
Optimizing the management of drug therapies
Pharmacists are playing a critical drug safety role in hospitals. Synapse Platform’s medication reconciliation solution was built to support you on a daily basis through all your clinical pharmacy activities.
Synapse Platform helps you with the medication reconciliation process by optimizing the management of drug therapies and strengthening coordinated care.
Access reliable and up-to-date medical information.
With Synapse Platform, hospital pharmacists can analyze whether one or more treatments present drug-related risks based on the patient's clinical characteristics: contraindications, drug interactions, adverse drug effects, and STOPP criteria. This allows healthcare professionals to optimize the management of drug treatments and ensure their patients' safety.
Improving clinical trial safety with Synapse Platform’s proprietary Medication Intelligence technology
Synapse Medicine's team is involved in ambitious clinical research projects related to proper drug use. These innovative collaborations allow us to develop our position as international leaders in the use of drug data in hospitals.
The PRoSIT project
A unique consortium of France’s top university hospitals, Inserm, and Synapse Medicine conducted a scientific study on drug interactions as part of the French Ministry for Health's 2019 French Research Program on Performance of Healthcare Systems (PREPS).
Our Co-founder and Medical Director’s scientific publications
Louis Létinier MD-PhD, one of the Co-founders and the Medical Director of Synapse Medicine, worked as a hospital pharmacologist at Bordeaux University Hospital. His pharmacological expertise shines through Synapse Platform and his numerous scientific publications:
Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France…
Létinier L, Cossin S, Mansiaux Y, Arnaud M, Salvo F, Bezin J, Thiessard F, Pariente A.
Impact of cancer diagnosis on persistence of oral antidiabetic drugs.
Létinier L, Mansiaux Y, Pariente A, Fourrier-Réglat A.
Psychoactive substances: Pharmacokinetic clues for harm…
Daveluy A, Géniaux H, Baumevieille M, Letinier L, Matta MN, Lazès-Charmetant A, Haramburu F, Guéroult P
Pharmacological treatments of cardiovascular diseases: Evidence…
Salvo F, Bezin J, Bosco-Levy P, Letinier L, Blin P, Pariente A, et al.
PRognostic factor of Early Death In phase II Trials or the end of …
Grellety T, Cousin S, Letinier L, Bosco-Lévy P, Hoppe S, Joly D, et al.